JUST IN
Reliance Power Q3 loss widens to Rs 291 cr, expenses rise to Rs 2,126 cr
LG Electronics Q4 profit collapses on slumping demand, rising cost
NTPC net profit up nearly 5% at Rs 4,854 crore in Q3 on higher revenue
Aditya Birla Sun Life AMC Q3 profit after tax declines 11% to Rs 166 crore
Patanjali Foods Q3 profit rises 15% to Rs 269 crore on better sales
Low output pulls Vedanta net profit down 41% to Rs 2,464 crore in Q3
Sterlite Technologies posts 13.6% rise in Dec quarter profit to Rs 50 cr
Bajaj Finance Q3 net up 40% to Rs 2,973 cr; highest ever quarterly profit
Bajaj Finance net profit jumps 40% in Q3 to Rs 2,973 crore; AUM up 27%
Best Agrolife Q3 net profit jump 98% to Rs 30.61 cr; revenue up 41%
You are here: Home » Companies » Results
DLF's net profit up 35% in Q3, total revenue falls to Rs 1,560 crore
icon-arrow-left
Private banks post 31.7% YoY growth in Q3, net profit rises to Rs 35,166 cr
Business Standard

Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23

Topics
Torrent Pharmaceuticals | Q3 results | EBITDA

Sohini Das  |  Mumbai 

Torrent Pharmaceuticals
Torrent Pharma’s US revenues were up by 24 percent during the quarter to Rs 291 crore, while in constant currency terms it was up 13 percent.

Ahmedabad-based Torrent Pharmaceuticals posted a 14 per cent rise in net profit for the third quarter of the 2022-23 fiscal to Rs 249 crore on the back of good growth in the India and Brazil markets.

Torrent Pharma’s revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23.

India, Torrent’s key market, grew by 17 per cent to Rs 1,259 crore including revenues from the integration of its recently acquired outfit Curatio Healthcare (a dermatology firm). “Field force has been further expanded and medical representative strength now stands at 5,300 including Curatio divisions,” the company said.

Meanwhile, the Brazil revenues were up 36 per cent to Rs 248 crore. In constant currency terms, however, the revenues from Brazil were up 17 percent. The growth was aided by the performance of top brands and market share gain and strong momentum in the generic segment.

Torrent Pharma’s US revenues were up by 24 per cent during the quarter to Rs 291 crore, while in constant currency terms, it was up 13 per cent.

Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

Read our full coverage on Torrent Pharmaceuticals

First Published: Wed, January 25 2023. 22:45 IST

`
RECOMMENDED FOR YOU
.